PodcastThe Directors The Directors: Directors of two Midwestern cancer centers tell us about the challenging healthcare economics in rural areas“Institutions are feeling crunched in so many different directions” June 26, 2026Vol.52 No.25By Paul Goldberg and Claire Marie Porter
Regulatory News To keep the early clinical trial enterprise in the U.S., HHS pledges to simplify regulatory requirements June 26, 2026Vol.52 No.25By Paul Goldberg
FreeObituary Joe Fraumeni, founder of molecular epidemiology, dies at 93“It’s hard to imagine a world without the presence of this gentle scientific giant.” June 26, 2026Vol.52 No.25By Stephen J. Chanock
FreeObituary Karen Huntsman’s vision gave shape to the Huntsman Cancer Institute June 26, 2026Vol.52 No.25By Bradley Cairns
FreeIn the Archives Robert Mayer tells us about pancreatic cancer’s hopeless past as new data shows promise June 26, 2026Vol.52 No.25By Sara Willa Ernst
Regulatory News Is psilocybin heading to a cancer clinic near you?Reversing Nixon-era taboo, Trump orders FDA to fast-track psychedelics and ARPA-H to fund research June 18, 2026Vol.52 No.24By Sara Willa Ernst
Trials & Tribulations What NHS-Galleri taught us—and what it didn’t June 18, 2026Vol.52 No.24By Scott D. Ramsey and Ruth Etzioni
Trials & Tribulations The NHS-Galleri trial has and will continue to provide critical insights to refine future MCED studies June 18, 2026Vol.52 No.24By Bryan Bassig, Catherine R. Marinac, David M. Routman, Elizabeth K. O'Donnell, Jennifer Keating Litton, Karthik V. Giridhar, Kennedy Ng Yao Yi, Kurt Giles, Nima Nabavizadeh, Ora K. Gordon, Rebecca Kaltman and Shawn Kothari
News Analysis FDA clears a way for dramatic reduction in animal toxicology studies in cancer June 18, 2026Vol.52 No.24By Claire Marie Porter
Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” June 12, 2026Vol.52 No.23By Jacquelyn Cobb
